Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor to Genentech’s eye drug Vabysmo.
Jason Ehrlich, Ollin Biosciences CEO
June 24, 2026 07:00 AM EDT
FinancingStartups
Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China
Lei Lei Wu
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a…
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3…
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19,…
San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
AbCellera raises $200M after Phase 2 win; Silence Therapeutics raises $175M post-Phase 2 success in rare blood cancer; InduPro…
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
Ophthalmology venture grabs investors’ attention, raises $330 million
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
